EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024)

Dahee Jung iD, Sreedharan Sabarinath iD, Ramana Uppoor iD, Mehul Mehta iD, Yifei Zhang iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70108 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Dahee Jung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropsychiatric Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research…. Hauptthemen laut MEDLINE: Drug Approval, Biomarkers, Nervous System Diseases, Drug Development. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past 15 years, biomarkers have evolved into a significant component of neurological drug development and regulatory evaluation, with expanded roles and increasing impact. This landscape analysis covers new molecular entity (NME) products approved by Food and Drug Administration from 2008 to 2024 for neurological diseases, which demonstrates the growing utilization of biomarkers in regulatory decision making. This includes their use as surrogate endpoints, confirmatory evidence, and basis for dose selection. Our analysis suggested prominent roles of biomarkers in various therapeutic modalities, including small molecules, oligonucleotides, and monoclonal antibodies, as well as in the context of rare or slowly progressive diseases. However, several challenges hinder the effective utilization of biomarker data, including lack of established clinical relevance, variability in data quality, and bioanalytical issues. Addressing these challenges will require cross‐sector collaboration, rigorous analytical validation, and a clear demonstration of the linkage between biomarker changes and meaningful clinical benefits. By strengthening the evidentiary foundation of biomarker data, stakeholders can accelerate innovative drug development for neurological diseases and other therapeutic areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalBiomarkersNervous System DiseasesDrug DevelopmentHumansUnited States Food and Drug AdministrationUnited StatesDecision Making

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Division of Neuropsychiatric Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.

ORCID-Profile: Dahee Jung, Sreedharan Sabarinath, Ramana Uppoor, Mehul Mehta, Yifei Zhang

Förderung

  • Intramural FDA HHS

Zitieren

APA

Jung, D., Sabarinath, S., Uppoor, R., Mehta, M., & Zhang, Y. (2026). Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70108

Vancouver

Jung D, Sabarinath S, Uppoor R, Mehta M, Zhang Y. Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024). Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70108

BibTeX
@article{Jung2026,
  author = {Jung, Dahee and Sabarinath, Sreedharan and Uppoor, Ramana and Mehta, Mehul and Zhang, Yifei},
  title = {Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024)},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70108}
}
Kostenlos starten →